Mercer Global Advisors Inc. ADV Has $1.25 Million Holdings in Haleon plc (NYSE:HLN)

Mercer Global Advisors Inc. ADV lifted its stake in shares of Haleon plc (NYSE:HLN) by 7.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 150,817 shares of the company’s stock after buying an additional 10,577 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Haleon were worth $1,246,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Cultivar Capital Inc. acquired a new position in shares of Haleon during the second quarter worth $40,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Haleon during the first quarter worth $43,000. GAMMA Investing LLC increased its holdings in shares of Haleon by 151.3% during the first quarter. GAMMA Investing LLC now owns 6,106 shares of the company’s stock worth $52,000 after buying an additional 3,676 shares in the last quarter. Pinnacle Bancorp Inc. increased its holdings in shares of Haleon by 29.8% during the first quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company’s stock worth $53,000 after buying an additional 1,421 shares in the last quarter. Finally, Hexagon Capital Partners LLC increased its holdings in Haleon by 66.6% in the second quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock valued at $55,000 after purchasing an additional 2,677 shares during the period. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Performance

Shares of Haleon stock opened at $10.67 on Wednesday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average price of $9.84 and a two-hundred day moving average price of $8.91. Haleon plc has a 1-year low of $7.70 and a 1-year high of $10.76. The company has a market cap of $48.72 billion, a P/E ratio of 35.57, a PEG ratio of 3.10 and a beta of 0.26.

Haleon (NYSE:HLN) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The business had revenue of $3.50 billion for the quarter, compared to analyst estimates of $3.55 billion. During the same quarter in the previous year, the business posted $0.08 earnings per share. As a group, analysts anticipate that Haleon plc will post 0.46 EPS for the current year.

Haleon Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Thursday, September 19th. Shareholders of record on Friday, August 16th were issued a dividend of $0.0514 per share. The ex-dividend date was Friday, August 16th. This represents a yield of 1.6%. Haleon’s payout ratio is currently 33.33%.

Analyst Ratings Changes

HLN has been the subject of a number of recent research reports. The Goldman Sachs Group downgraded Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Berenberg Bank initiated coverage on Haleon in a report on Tuesday, August 6th. They issued a “buy” rating for the company. Finally, Morgan Stanley increased their price objective on Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a report on Friday, September 20th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.